Kinetics of 111In-labeled bleomycin in patients with brain tumors: Compartmental vs. non-compartmental models

Annals of Nuclear Medicine

Volumn 12, Issue 6, 1998, Pages 313-321

  Ryynänen, Päivi M ^b   Savolainen, Sauli E ^a   Aronen, Hannu J ^b   Korppi Tommola, E Tapani ^b   Huhmar, Helena M ^b   Kallio, Merja E ^b   Hiltunen, Jukka V ^b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b NONE

Author keywords

111In bleomycin; Brain tumors; Compartmental models; Exponential fit; Modeling

Indexed keywords

BLEOMYCIN IN 111; BLEOMYCIN; BLEOMYCIN INDIUM; DRUG DERIVATIVE; INDIUM; INDIUM-BLEOMYCIN; ORGANOMETALLIC COMPOUND;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; BRAIN SCINTISCANNING; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG BLOOD LEVEL; DRUG URINE LEVEL; FEMALE; GLIOMA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MENINGIOMA; PLASMA CLEARANCE; PREDICTION; PRIORITY JOURNAL; RADIOISOTOPE DISTRIBUTION; ADENOCARCINOMA; BIOLOGICAL MODEL; BLOOD; BRAIN TUMOR; COMPARATIVE STUDY; METABOLISM; METASTASIS; MIDDLE AGED; STATISTICAL ANALYSIS;

ADENOCARCINOMA; ADULT; AGED; BLEOMYCIN; BRAIN NEOPLASMS; DATA INTERPRETATION, STATISTICAL; FEMALE; GLIOMA; HUMANS; INDIUM RADIOISOTOPES; MALE; MENINGIOMA; MIDDLE AGED; MODELS, BIOLOGICAL; ORGANOMETALLIC COMPOUNDS;

EID: 0032216730     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03164920     Document Type: Article

References (41)

1. Green MH. Introduction to modelling. J Nutr 122: 690-694, 1992.
2. Pilo A, Iervasi G, Vitek F, Ferdeghini M, Cazzuola F, Bianchi R. Thyroidal and peripheral production of 3,5,3′-triiodothyronine in humans by multicompartmental analysis. Am Phys Soc, 1990.
3. Vera DR, Woodle S, Stadalnik RC. Kinetic sensitivity of a receptor-binding radiopharmaceutical: technetium-99m galactosyl-neoglycoalbumin. J Nucl Med 30: 1519-1530, 1989.
4. Savolainen S, Syrjälä MT, Liewendahl K, Gripenberg J, Nieminen U. Compartmental analysis of short-lived platelet dynamics. Scand J Clin Lab Inv 50: 679-686, 1990.
5. Savolainen S, Liewendahl K, Syrjälä MT, Gripenberg J. Platelet splenic transit times in idiopathic thrombocytopenic purpura; compartmental vs. non-compartmental model. Int J Hematol 55: 81-87, 1992.
6. Feldman HA. A numerical method for fitting compartmental models directly to tracer data. Am J Phys 233 (1): R1-R7, 1977.
7. Berman M. A postulate to aid in model building. J Theor Biol 4: 229-236, 1963.
8. Sweetlove MA, Lötter MG, Roodt JP, Badenhorst PN, Kotzé HF, Heyns AdP. Blood platelet kinetics in normal subjects modelled by compartmental analysis. Eur J Nucl Med 19: 1023-1031, 1992.
9. Ceberg CP, Brun A, Kahl SB, Koo MS, Persson BRR, Salford LG. A comparative study on the pharmacokinetics and biodistribution of boronated porphyrin (BOPP) and sulfhydryl boron hydride (BSH) in the RG2 rat glioma model. J Neurosurg 83: 86-92, 1995.
10. Rubinow SI, Winzer A. Compartment analysis: an inverse problem. Math Biosci 11: 203-347, 1971.
11. Lassen NA, Perl W. Tracer Kinetic Method in Medical Physiology. New York: Raven Press, 1979.
12. Kuikka JT, Bassingthwaighte JB, Henrich MM, Feinendegen LE. Mathematical modelling in nuclear medicine. Eur J Nucl Med 18 (5): 352-362, 1991.
13. van der Woude FJ, Beekhuis H, Beelen JM, The TH. Kinetic analysis of the blood clearance and organ uptake curves of IgG-coated red cells in HLA-typed controls and patients with Wegener's granulomatosis. Eur J Nucl Med 12: 130-136, 1986.
14. Brownell GL, Berman M, Robertson JS. Nomenclature for tracer kinetics. Int J Appl Rad Isot 19: 249-262, 1968.
15. Peters AM. A unified approach to quantification by kinetic analysis in nuclear medicine. J Nucl Med 34: 706-713, 1993.
16. Syrjälä MT, Savolainen S, Nieminen U, Gripenberg J, Liewendahl K, Ikkala E. Splenic dynamics of Indium-111 labeled platelets in idiopathic thrombocytopenic purpura. J Nucl Med 30: 1546-1549, 1989.
17. Lampinen J, Pohjonen H, Savolainen S. Calculating internal dose by convolution from SPECT/MR fusion images. Ann Nucl Med 12: 1-5, 1998.
18. ICRP: Radiation dose to patients from radiopharmaceuticals, Annals of the ICRP, Pergamon Press, 1987.
19. Strand SE, Zanzonico P, Johnson TK. Pharmacokinetic modeling. Med Phys 20 (2): 515-527, 1993.
20. van Osdol WW, Sung C, Dedrick RL, Weinstein JN. A distributed pharmacokinetic model of two-step imaging and treatment protocols: application to streptavidin-conjugated monoclonal antibodies and radiolabelled biotin. J Nucl Med 34: 1552-1564, 1993.
21. Barranco SC, Humphrey RM. The effects of bleomycin on survival and cell progression in Chinese hamster cells in vivo. Cancer Res 31: 1218-1223, 1971.
22. Dorr RT. Bleomycin pharmacology: mechanism of action and resistance, and clinical pharmacokinetics. Sem Oncol 19 (2 Suppl 5): 3-8, 1992.
23. Hou D-Y, Hoch H, Johnston GS, Tsou KC, Farkas RJ, Miller EE. Use of 111-In-bleomycin for combining radiotherapy and chemotherapy on glioma-bearing mice. J Surg Oncol 29: 71-77, 1985.
24. Thakur ML, Merrick MV, Gunasekera SW. Some pharmacological aspects of a new radiopharmaceutical, 111-In-bleomycin. Radiopharmaceuticals and Labelled Compounds. Vienna, International Atomic Energy Agency, 1973, pp. 183-193.
25. Williams ED, Merrick MV, Lavender JP. The distribution and dosimetry of 111-In-bleomycin in man. Brit J Rad 48: 275-278, 1975.
26. Kairemo KA, Ramsay HA, Tagesson M, Jekunen AP, Paavonen TK, Jääskelä-Saari HA, et al. Indium-111 bleomycin complex for radiochemotherapy of head and neck cancer - dosimetric and biokinetic aspects. Eur J Nucl Med 23: 631-638, 1996.
27. Huhmar H, Korppi-Tommola T, Aronen H, Kallio M, Färkkilä M, Penttilä P, et al. 111-In-labeled bleomycin uptake by brain tumours. Eur J Nucl Med 22 (8): 869, 1995.
28. Kleihues P, Burher PC, Scheithauer BW. The new WHO classification of brain tumours. Brain Path 3: 255-268, 1993.
29. Hou D-Y, Maruyama Y. Distribution of 111-In-bleomycin complex in small lung cancer cells by autoradiography. J Surg Oncol 49: 93-97, 1992.
30. Guardabasso V, Munson PJ, Rodbard D. EXPFIT - A basic computer program for simultaneous curve fitting of a family of multi-exponential decay-curves, user's guide. Maryland: National Institute of Child Health and Human Development, 1989.
31. Resigno A, Segre G. Drug and Tracer Kinetics. Massachusetts: Blaisdell Publishing Company, 1966.
32. RFKA. SAAM II user guide. Seattle: University of Washington, 1994
33. Chabner BA. Chemotherapy - principles and practice, Cancer Chemotherapy - Principles and Practice. Chabner BA, Collins JM (eds.), Philadelphia: J.B. Lippincott Company, 1990, pp. 341-355.
34. Bard Y. Comparison of gradient methods for the solution of nonlinear parameter estimation problems. SIAM J Num Anal 7 (1): 157-186, 1970.
35. Lemaitre A, Malengé J-P. An efficient method for multi-exponential fitting with a computer. Comp Biomed Res 4: 555-560, 1971.
36. Provencher SW. A Fourier method for the analysis of exponential decay curves. Biophys J 16: 27-41, 1976.
37. Pitkänen MA, Kuikka JT, Kiiliäinen H, Macey DJ. Comparison of two optimizing algorithms for cerebral blood flow analysis using the intravenous 133-Xe wash-out method. Int J Bio-Med Comp 13: 216-220, 1982.
38. Sperber GO, Ericsson A, Fransson A, Hemmingsson A. Fast methods for fitting biexponentials especially applicable to MRI multiecho data. Phys Med & Biol 35 (3): 399-411, 1990.
39. Gambhir SS, Hawkins RA, Huang S-C, Hall TR, Busuttil RW, Phelps ME. Tracer kinetic modeling approaches for the quantification of hepatic function with technetium-99m DISIDA and scintigraphy. J Nucl Med 30: 1507-1518, 1989.
40. Crooke ST, Luft F, Broughton A. Bleomycin serum pharmacokinetics as determined by a radioimmunoassay and a microbiologic assay in a patient with compromised renal function. Cancer 39: 1430-1434, 1977.
41. Skinner SM, Clasrk RE, Baker N, Shipley A. Complete solution of the three-compartment model in a steady state after single injection of radioactive tracer. Am J Phys 196: 238-244, 1959.